BAXCAUTIOUS

Revenue Growth (YoY)

2.9%

Higher than 38% of Healthcare sector peers

Updated 80h ago

Sector Performance

38th percentile

BAX

2.9%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Baxter’s revenue growth (year-over-year, or YoY) of 2.9% means the company’s sales increased by 2.9% compared to the same quarter last year, a common measure of top-line expansion.

This growth rate is below the healthcare sector median of 6.2%, placing Baxter in the 38th percentile among its peers. The trend for this metric is not available (N/A), and both the year-over-year change and quarter-over-quarter change are also listed as N/A, meaning no historical trend data is provided for analysis. The combination of a revenue growth level that lags the sector median and the absence of trend data creates uncertainty about whether performance is improving or eroding, increasing investment risk. This metric directly contradicts the overall cautious verdict only in the sense that a below-median growth rate supports the need for caution, rather than a bullish outlook.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about BAX?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does BAX's Revenue Growth (YoY) compare to its sector?

BAX's Revenue Growth (YoY) of 2.9% compares to a Healthcare sector median of 6.2%, placing it in the 38th percentile.

Who are BAX's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.